ALXN : Analysis & Opinions

  1. Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst ...

    January 28, 2015
    Amgen continued with its strong performance in Q4 with the company surpassing expectations yet again.
  2. Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - ...

    January 27, 2015
    Gilead Sciences, Inc. (GILD) expanded HCV licensing agreements with India-based partners to include an investigational pan-genotypic ...
  3. The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst ...

    January 27, 2015
    The Medicines Company (MDCO) announced that the CHMP has issued positive opinions regarding the marketing authorization for ...
  4. Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst ...

    January 27, 2015
    Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report its fourth-quarter 2014 results on Jan 29, before the opening ...
  5. Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst ...

    January 23, 2015
    Minerva Neurosciences, Inc. announced encouraging preliminary results from a phase I study on its sleep disorder candidate, ...
  6. Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst ...

    January 23, 2015
    The EC has approved Sanofi's (SNY) Cerdelga for the treatment of certain adults suffering from Gaucher disease type I.
  7. BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst ...

    January 22, 2015
    BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa ...
  8. Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst ...

    January 22, 2015
    Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense ...
  9. Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst ...

    January 22, 2015
    Endo International has priced $1.2 billion aggregate principal amount of 6.00% senior notes due Feb 2025 at par with a face ...
  10. Keryx to Raise $110 Million Through Issuance of Shares - Analyst ...

    January 22, 2015
    Keryx (KERX) will be raising $110 million through the issuance of the shares with plans to invest the funds on the ongoing ...
  11. Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst ...

    January 22, 2015
    Arena Pharmaceuticals (ARNA) announced that it will be selling 21 million shares in an underwritten public offering of common ...
  12. Merrimack Reveals Additional Data from Oncology Candidate - Analyst ...

    January 22, 2015
    Merrimack (MACK) announced additional analyses from the phase III NAPOLI-1 study on MM-398 .
  13. Celgene to Use Zymeworks' Azymetric Platform for New Drugs - ...

    January 22, 2015
    Celgene (CELG) inked a deal with Zymeworks for the research, development and commercialization of bi-specific antibody therapeutics.
  14. Alnylam to Raise $450 Million Through Issuance of Shares - Analyst ...

    January 21, 2015
    Alnylam (ALNY) will be raising $450 million through the issuance of shares with plans to invest the funds across its pipeline.
  15. Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst ...

    January 21, 2015
    Shares of Affymetrix Inc. (AFFX) scaled a new 52-week high of $11.89 on Jan 20, eventually closing at $11.65.
  16. Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst ...

    January 20, 2015
    Zacks Investment Research downgraded Supernus Pharmaceuticals (SUPN) to a Zacks Rank #4 (Sell) on Jan 20.
  17. Celgene Up as Otezla Gains EU Approval for Two Indications - ...

    January 19, 2015
    Celgene Corporation announced that the European Commission has granted approval to Otezla for two therapeutic indications.
  18. Illumina Unveils 3 NGS Systems, Modifies Business Strategy - ...

    January 16, 2015
    llumina's (ILMN) NextSeq 550 System is the first next generation sequencer that allows array scanning.
  19. OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst ...

    January 16, 2015
    OncoMed Pharmaceuticals, Inc. (OMED) has enrolled the first biomarker-selected patient in the expansion stage of a phase ...
  20. Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - ...

    January 15, 2015
    Sarepta Therapeutics Inc. (SRPT) announced that it has initiated dosing its first patient in a phase I/II study on SRP-4 ...
  21. Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst ...

    January 15, 2015
    Illumina (ILMN) estimates total revenue of $512 million for the yet to-be-reported fourth quarter, which reflects a massive ...
  22. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  23. Regado Biosciences to Merge with Tobira Therapeutics - Analyst ...

    January 15, 2015
    Regado Biosciences announced that it has entered into a definitive merger agreement with privately-held Tobira Therapeutics, ...
  24. Qiagen Up on CE-IVD Mark for New Liquid Biopsy Test Kit - Analyst ...

    January 15, 2015
    Qiagen (QGEN) currently offers the therascreen EGFR test as a tissue-based companion diagnostic for lung cancer patients ...
  25. BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst ...

    January 14, 2015
    BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II ...
  26. Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal ...

    January 14, 2015
    Qiagen (QGEN) expects this buyout to provide approximately $20 million CER (constant exchange rates) of incremental net sales
  27. Celgene's Preliminary Results & 2015 Outlook Encouraging - Analyst ...

    January 13, 2015
    Celgene Corporation (CELG) provided encouraging guidance for 2015.
  28. Pharmacyclics Reports Preliminary Results and 2015 Outlook - ...

    January 13, 2015
    Pharmacyclics, Inc. (PCYC) provided preliminary 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook ...
  29. Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst ...

    January 13, 2015
    Biogen's (BIIB) upcoming acquisition of Convergence should strengthen its pain pipeline.
  30. Seattle Genetics, Bristol-Myers to Study Adcetris-Opdivo - Analyst ...

    January 13, 2015
    Seattle Genetics, Inc. (SGEN) and partner Bristol-Myers Squibb Company inked a deal to develop an investigational combination ...
  31. Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst ...

    January 13, 2015
    Qiagen's (QGEN) QIAsymphony automation solution refers to a revolutionizing molecular testing workflow which offers flexible ...
  32. Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst ...

    January 12, 2015
    Regeneron and Sanofi announced that the Marketing Authorisation Application for Praluent has been accepted by the European ...
  33. Emergent BioSolutions Provides Preliminary 2014 Results - Analyst ...

    January 12, 2015
    Emergent BioSolutions (EBS) announced preliminary results for 2014 and provided an outlook for 2015.
  34. Argos Therapeutics Falls on Disappointing Phase IIb HIV Data ...

    January 12, 2015
    Argos Therapeutics Inc.'s (ARGS) AGS-004 failed to meet the primary endpoint in a phase IIb study for the treatment of patients ...
  35. Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - ...

    January 12, 2015
    Vertex Pharmaceuticals (VRTX) provided an update on its cystic fibrosis pipeline and issued preliminary financial guidance ...
  36. Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog

    January 12, 2015
    Qiagen's (QGEN) QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection.
  37. Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst ...

    January 12, 2015
    Provider of life science tools and molecular diagnostic products, Affymetrix, Inc. (AFFX), is expected to highlight various ...
  38. Bristol-Myers Opdivo Study Stopped on Favorable Data - Analyst ...

    January 12, 2015
    Bristol-Myers Squibb Company (BMY) announced that a phase III study on Opdivo, was stopped early because the independent ...
  39. Alexion Reports Disappointing Phase II Data on Soliris - Analyst ...

    January 8, 2015
    Alexion Pharmaceuticals, Inc. reported disappointing data from a phase II study evaluating Soliris for the prevention of ...
  40. Alexion Seeks FDA Approval for its Hypophosphatasia Drug - Analyst ...

    December 31, 2014
    Alexion Pharmaceuticals is looking to get asfotase alfa approved in the U.S. for treating patients suffering from hypophosphatasia.
  41. Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx ...

    December 17, 2014
    It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline ...
  42. Alexion Announces New Share Repurchase Program of $500M - Analyst ...

    December 16, 2014
    Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized ...
  43. Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst ...

    December 15, 2014
    Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
  44. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  45. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  46. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  47. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  48. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  49. Alexion Pharmaceuticals and Other Nasdaq Stocks Making Big Moves ...

    January 2, 2013
    After this morning's trading, the market is looking good. The Nasdaq is trading up 2.3%; the S&P 500 is up 1.8%; and ...
  50. Alexion Pharmaceuticals and More Big Movers in Healthcare on ...

    December 7, 2012
    So far today, the Nasdaq is down 0.7%, the S&P 500 is unchanged and the Dow is trading up 0.3%. The healthcare sector ...
  51. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  52. Healthcare Stocks, Including Eli Lilly, Making Big Moves on August ...

    August 24, 2012
    The Nasdaq has increased 0.6%, the S&P 500 has risen 0.5% and the Dow has moved up 0.6% on a good day for the market ...
  53. Biggest Healthcare Sector Movers, Including ALXN

    August 3, 2012
    On a good day for the market, the Nasdaq has climbed 2.2%, the S&P 500 has increased 2% and the Dow is up 1.8%. The healthcare ...
  54. 5 Medical Stocks with Healthy Charts

    February 14, 2012
    Within the health-care sector are some companies with a good mix of technical and fundamental promise. However, some are ...
  55. Big Bets on High-Flying Pharma Stock

    February 9, 2012
    Following bullish earnings, Karee Venema of Schaeffer’s Research writes that call buyers are piling in to one biopharmaceutical ...
  56. Healthcare Stocks On The Move

    December 13, 2011
    These four healthcare stocks are showing above-average performance.
  57. Should Biotech Investors Go Where Institutions Won't?

    July 7, 2011
    A lack of institutional ownership should be a warning sign for biotech investors.
  58. Drug Manufacturers Showing Strength

    November 16, 2010
    Drug Manufacturers Showing Strength
Trading Center